- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07332351
Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial (TRIFECTA)
Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)
This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with enfortumab vedotin and pembrolizumab before (neoadjuvant) radical cystectomy in treating patients with muscle invasive bladder cancer. The combination of enfortumab vedotin and pembrolizumab are already considered standard of care in the treatment of muscle invasive bladder cancer. This trial attempts to determine whether the addition of nadofaragene firadenovec to the current standard regiment is safe and can improve oncological outcomes for those with muscle invasive bladder cancer.
Nadofaragene firadenovec, a type of intravesical gene therapy, is a weakened adenovirus that carries a copy of the gene for interferon alfa-2b. This medication gets absorbed by the bladder and stimulates the bladder to naturally create interferon alfa-2b, which is thought to kill bladder cancer. Nadofaragene firadenovec is given in a solution that is placed directly into the bladder (intravesical) using a thin tube called a catheter. It is a medication that is already Food and Drug Administration approved for the treatment of non-muscle invasive bladder cancer.
Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread.
Investigators aim to assess whether adding intravesical nadofaragene firadenovec to the current recommended treatment of enfortumab vedotin and pembrolizumab before undergoing a radical cystectomy may be safe, tolerable, and/or effective in treating patients with muscle-invasive bladder cancer.
Study Overview
Status
Conditions
Detailed Description
OUTLINE:
Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin intravenously (IV) on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity. In addition, patients will also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (one total dose during the entire neoadjuvant period). Starting 4-8 weeks after completion of treatment, patients undergo radical cystectomy (RC) per standard clinical care. Additionally, patients undergo urine and blood sample collection and computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT throughout the study.
After completion of study treatment, patients are followed for up to 30 days post-cystectomy to monitor for adverse events.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jonathan Wright, MD
- Phone Number: 206-598-4294
- Email: jlwright@uw.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
Principal Investigator:
- Jonathan Wright, MD
-
Contact:
- Jonathan Wright, MD
- Phone Number: 206-598-4294
- Email: jlwright@uw.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years at the time of screening
- Ability to understand and willingness to sign the written informed consent document
- Patients with confirmed muscle-invasive urothelial carcinoma of the bladder (cT2-4a, N0-1, M0 or cT1, N1, M0), who are planning to undergo RC
- Pure urothelial or mixed histologic subtypes are allowed if urothelial is the primary histology (regardless of the % of conventional urothelial histology; however, any % of small cell/neuroendocrine is excluded)
- Eligible to receive neoadjuvant enfortumab vedotin and pembrolizumab (EV-P) per the patient's medical oncologist's discretion
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Hemoglobin ≥ 9 g/dL
- Absolute neutrophil count of ≥ 1500 cells/uL
- Platelet count of ≥ 100,000/uL
- Alanine and aspartate aminotransferase levels ≤ 2.5 x upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN for Gilbert syndrome)
- Creatinine clearance or estimated glomerular filtration rate (GFR) ≥ 30ml/min (using Chronic Kidney Disease Epidemiology Collaboration Formula [CKD-EPI] 2021 or Cockcroft-Gault equation)
- For patients with evidence of, or history of HIV, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, the viral load must be undetectable, or the infection must have been treated and cured. Patients are not allowed to be on therapy agents given for HIV, HBV or HCV. Routine testing for HIV, HBV and HCV is not required for patients without such history unless clinically indicated
- Individuals with prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll
Exclusion Criteria:
- cT4b, N2-3, or M1 clinical stage at time of screening
- Any known concurrent clinically relevant malignancies (discussion with trial principal investigator [PI] can be considered)
- Prior systemic therapy for MIBC or non-muscle invasive bladder carcinoma (NMIBC)
- Current or prior use of systemic immunosuppressive medication within 14 days before first dose of investigational product. The following are allowed (not systemic route): intranasal, inhaled, intra-auricular, intra-articular, topical steroids, local steroid injections
- Pure non-urothelial histology subtype/variant or any neuroendocrine (small or large cell) component
- Prior treatment with adenovirus-based drugs
- Known hypersensitivity or allergy to any components of rAd-interferon (IFN)a/Syn3
- Currently receiving other investigational agent
- Pregnant or lactating women
- Inability to comprehend and provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment
Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin IV on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. In addition, patients also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (total of 1 dose in neoadjuvant period). Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Starting 4-8 weeks after treatment, patients undergo RC per standard clinical care. Additionally, patients undergo urine and blood sample collection and CT, MRI or PET/CT throughout the study. |
Undergo MRI
Other Names:
Given IV
Other Names:
Undergo CT or PET/CT
Other Names:
Undergo PET/CT
Other Names:
Given IV
Other Names:
Undergo urine and blood sample collection
Other Names:
Given intravesically
Other Names:
Undergo RC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients who receive nadofaragene firadenovec and complete at least 2 cycles of enfortumab vedotin and pembrolizumab in the neoadjuvant period followed by radical cystectomy
Time Frame: Within 10 weeks from last neoadjuvant therapy dose
|
Will be calculated as the number of patients who complete the planned course divided by the total number of enrolled patients who initiate therapy. Exact 95% confidence intervals will be reported. Reasons for non-completion will be summarized descriptively. |
Within 10 weeks from last neoadjuvant therapy dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of grade 3 or higher treatment-related adverse events (AE)
Time Frame: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
Will be graded by provider-scored toxicity via the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Will be summarized descriptively, including the number and proportion of patients experiencing at least one grade ≥ 3 AE, and the type, severity, and relatedness of all treatment-related AEs, attributed by agent. |
From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
|
Incidence of AEs
Time Frame: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
Will be summarized by maximum CTCAE grade and relatedness to the treatment. |
From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
|
Pathologic complete response (pCR) on radical cystectomy (RC) specimen
Time Frame: At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
Will be defined as the proportion of participants achieving ypT0N0. Will assume the null hypothesis that the true pCR rate is 56 % with the alternative hypothesis of 65%. The observed pCR rate will be reported with an exact 95% confidence interval using the Clopper-Pearson method. |
At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
|
Downstaging (≤ ypT1N0) on RC specimen
Time Frame: At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Wright, MD, Fred Hutch/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urologic Neoplasms
- Urinary Bladder Diseases
- Urinary Bladder Neoplasms
- Amino Acids, Peptides, and Proteins
- Nerve Tissue Proteins
- Proteins
- Investigative Techniques
- Surgical Procedures, Operative
- Chemistry Techniques, Analytical
- Spectrum Analysis
- Urologic Surgical Procedures
- Urogenital Surgical Procedures
- Phosphoproteins
- pembrolizumab
- Magnetic Resonance Spectroscopy
- enfortumab vedotin
- Cystectomy
- Synapsins
Other Study ID Numbers
- RG1126027
- NCI-2025-09407 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.